Arcoxia 90 mg reduces inflammation and pain, and is effective for both short-term and long-term use.
Etoricoxib
Nonsteroidal anti-inflammatory drug (NSAID)
Film-coated tablets:
60 mg – Green
90 mg – White
120 mg – Light green
Etoricoxib is a nonsteroidal anti-inflammatory drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which at therapeutic concentrations blocks prostaglandin synthesis, exhibiting anti-inflammatory, analgesic, and antipyretic effects.
Selective COX-2 inhibition with Etoricoxib leads to a significant reduction in clinical symptoms associated with inflammatory processes, without affecting platelet function or the gastrointestinal mucosa.
The COX-2 inhibition effect of Etoricoxib is dose-dependent. Daily doses up to 150 mg do not affect COX-1 activity. The drug does not influence prostaglandin production in the gastric mucosa or bleeding time. Studies have shown no reduction in arachidonic acid levels or collagen-induced platelet aggregation.
Hypersensitivity to any component of the drug
Complete or partial overlap with bronchial asthma and recurrent nasal polyposis
Intolerance to acetylsalicylic acid or other NSAIDs (including history)
Erosive or ulcerative lesions of the stomach or duodenum, active gastrointestinal bleeding
Cerebrovascular or other types of bleeding
Inflammatory bowel disease (Crohn's disease, ulcerative colitis) during exacerbation
Hemophilia or other coagulation disorders
Severe heart failure (NYHA II–IV)
Severe liver failure (Child-Pugh score >9) or active liver disease
Severe renal failure (creatinine clearance <30 ml/min) or progressive kidney disease
Confirmed hyperkalemia
Post-aortocoronary bypass period
Peripheral arterial disease
Cerebrovascular disease
Clinically significant ischemic heart disease
Uncontrolled severe arterial hypertension (≥140/90 mmHg)
Pregnancy and lactation
Children under 16 years
Special note: Etoricoxib may negatively affect female fertility and is not recommended for women planning pregnancy.
